After Iovance Biotherapeutics presented new data from Cohort 2 of the ongoing Phase 2 lifileucel metastatic melanoma study, Piper Jaffray analyst Joseph Catanzaro said the fact that median duration of response, or DOR, has not yet been reached at a median follow-up of 12.8 months per investigator assessment suggests durable responses are being seen with the drug. The analyst, who said he expects the data to continue to "mature favorably," sees ultimate implications on commercial adoption and peak penetration, he noted. He keeps an Overweight rating on Iovance shares.